Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

2(33.3%)

Phase 4

2(33.3%)

N/A

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 3(2)

Phase 4(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02066220Phase 2Active Not Recruiting

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Role: collaborator

NCT03327428Recruiting

Sickle-cell Disease Registry of the GPOH

Role: collaborator

NCT00876031Phase 3Completed

Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma

Role: collaborator

NCT03243461Phase 3Unknown

International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)

Role: collaborator

NCT01272622Not ApplicableCompleted

Prospective Study of Children and Adolescents With Craniopharyngioma

Role: collaborator

NCT01424839Phase 4Unknown

Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors

Role: collaborator

NCT00114348Phase 4Completed

ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia

Role: collaborator

All 7 trials loaded